BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 15310757)

  • 21. Increased osteoblast apoptosis in apert craniosynostosis: role of protein kinase C and interleukin-1.
    Lemonnier J; Haÿ E; Delannoy P; Fromigué O; Lomri A; Modrowski D; Marie PJ
    Am J Pathol; 2001 May; 158(5):1833-42. PubMed ID: 11337381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Negative autoregulation of fibroblast growth factor receptor 2 expression characterizing cranial development in cases of Apert (P253R mutation) and Pfeiffer (C278F mutation) syndromes and suggesting a basis for differences in their cranial phenotypes.
    Britto JA; Moore RL; Evans RD; Hayward RD; Jones BM
    J Neurosurg; 2001 Oct; 95(4):660-73. PubMed ID: 11596961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.
    Ibrahimi OA; Eliseenkova AV; Plotnikov AN; Yu K; Ornitz DM; Mohammadi M
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7182-7. PubMed ID: 11390973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice.
    Wang Y; Sun M; Uhlhorn VL; Zhou X; Peter I; Martinez-Abadias N; Hill CA; Percival CJ; Richtsmeier JT; Huso DL; Jabs EW
    BMC Dev Biol; 2010 Feb; 10():22. PubMed ID: 20175913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequence analysis of fibroblast growth factor receptor 2 ( FGFR2 ) in Japanese patients with craniosynostosis.
    Sakai N; Tokunaga K; Yamazaki Y; Shida H; Sakata Y; Susami T; Nakakita N; Takato T; Uchinuma E
    J Craniofac Surg; 2001 Nov; 12(6):580-5. PubMed ID: 11711827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activating (P253R, C278F) and dominant negative mutations of FGFR2: differential effects on calvarial bone cell proliferation, differentiation, and mineralization.
    Ratisoontorn C; Fan GF; McEntee K; Nah HD
    Connect Tissue Res; 2003; 44 Suppl 1():292-7. PubMed ID: 12952211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis.
    Kan SH; Elanko N; Johnson D; Cornejo-Roldan L; Cook J; Reich EW; Tomkins S; Verloes A; Twigg SR; Rannan-Eliya S; McDonald-McGinn DM; Zackai EH; Wall SA; Muenke M; Wilkie AO
    Am J Hum Genet; 2002 Feb; 70(2):472-86. PubMed ID: 11781872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Fgfr2(S252W/+) mutation in mice retards mandible formation and reduces bone mass as in human Apert syndrome.
    Zhou X; Pu D; Liu R; Li X; Wen X; Zhang L; Chen L; Deng M; Liu L
    Am J Med Genet A; 2013 May; 161A(5):983-92. PubMed ID: 23495007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis.
    Yin L; Du X; Li C; Xu X; Chen Z; Su N; Zhao L; Qi H; Li F; Xue J; Yang J; Jin M; Deng C; Chen L
    Bone; 2008 Apr; 42(4):631-43. PubMed ID: 18242159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome.
    Lomri A; Lemonnier J; Hott M; de Parseval N; Lajeunie E; Munnich A; Renier D; Marie PJ
    J Clin Invest; 1998 Mar; 101(6):1310-7. PubMed ID: 9502772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling.
    Miraoui H; Oudina K; Petite H; Tanimoto Y; Moriyama K; Marie PJ
    J Biol Chem; 2009 Feb; 284(8):4897-904. PubMed ID: 19117954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand.
    Anderson J; Burns HD; Enriquez-Harris P; Wilkie AO; Heath JK
    Hum Mol Genet; 1998 Sep; 7(9):1475-83. PubMed ID: 9700203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maldevelopment of the submandibular gland in a mouse model of apert syndrome.
    Yamaji K; Morita J; Watanabe T; Gunjigake K; Nakatomi M; Shiga M; Ono K; Moriyama K; Kawamoto T
    Dev Dyn; 2018 Nov; 247(11):1175-1185. PubMed ID: 30251381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [From gene to disease; craniosynostosis syndromes due to FGFR2-mutation].
    van Ravenswaaij-Arts CM; van den Ouweland AM; Hoogeboom AJ; Herbergs J; Pals G
    Ned Tijdschr Geneeskd; 2002 Jan; 146(2):63-6. PubMed ID: 11820058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FGFR2 mutations among Thai children with Crouzon and Apert syndromes.
    Shotelersuk V; Mahatumarat C; Ittiwut C; Rojvachiranonda N; Srivuthana S; Wacharasindhu S; Tongkobpetch S
    J Craniofac Surg; 2003 Jan; 14(1):101-4; discussion 105-7. PubMed ID: 12544231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast growth factor receptor-2 activation supports osteoblast differentiation.
    Kaabeche K; Lemonnier J; Le Mée S; Caverzasio J; Marie PJ
    J Biol Chem; 2004 Aug; 279(35):36259-67. PubMed ID: 15190072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genotype-phenotype analysis in Apert syndrome suggests opposite effects of the two recurrent mutations on syndactyly and outcome of craniofacial surgery.
    von Gernet S; Golla A; Ehrenfels Y; Schuffenhauer S; Fairley JD
    Clin Genet; 2000 Feb; 57(2):137-9. PubMed ID: 10735635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding the molecular basis of Apert syndrome.
    Ibrahimi OA; Chiu ES; McCarthy JG; Mohammadi M
    Plast Reconstr Surg; 2005 Jan; 115(1):264-70. PubMed ID: 15622262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Ser252Trp [corrected] substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis.
    Chen L; Li D; Li C; Engel A; Deng CX
    Bone; 2003 Aug; 33(2):169-78. PubMed ID: 14499350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FGFR2 mutation confers a less drastic gain of function in mesenchymal stem cells than in fibroblasts.
    Yeh E; Atique R; Ishiy FA; Fanganiello RD; Alonso N; Matushita H; da Rocha KM; Passos-Bueno MR
    Stem Cell Rev Rep; 2012 Sep; 8(3):685-95. PubMed ID: 22048896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.